Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Sep 8, 2022
- Accession no.
- 0001493152-22-025399
- Filed
- Sep 8, 2022
- Trade date
- Sep 6-7, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $237.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 | Common Stock | MOption exerciseAcquired | +9,166 | $1.74 | +$15,948.84 | 9,166 | Direct | |
| Sep 6, 2022 | Common Stock | SSaleDisposed | −4,422 | $17.94F2 | −$79,330.68 | 4,744 | Direct | |
| Sep 6, 2022 | Common Stock | SSaleDisposed | −4,138 | $18.98F3 | −$78,539.24 | 606 | Direct | |
| Sep 6, 2022 | Common Stock | SSaleDisposed | −606 | $19.78F4 | −$11,986.68 | 0 | Direct | |
| Sep 7, 2022 | Common Stock | MOption exerciseAcquired | +8,220 | $1.74 | +$14,302.8 | 8,220 | Direct | |
| Sep 7, 2022 | Common Stock | SSaleDisposed | −4.56 | $18.12F5 | −$82.63 | 3,658 | Direct | |
| Sep 7, 2022 | Common Stock | SSaleDisposed | −3,658 | $18.42F6 | −$67,380.36 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 6, 2022 | Common Stock | MOption exerciseDisposed | −9,166 | $0.00 | $0 | 45,348 | Direct | |
| Sep 7, 2022 | Common Stock | MOption exerciseDisposed | −8,220 | $0.00 | $0 | 37,128 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.56 to $18.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.57 to $19.50, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $19.595 to $20.075, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.32 to $18.32, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F6
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.345 to $18.625, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary